Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laura B. Faden
Observed names:
Laura B Faden,
Laura Faden
Institutions:
Harvard University,
Harvard Pilgrim Health Care
Observed institutions:
Tufts University,
Harvard University,
Harvard Pilgrim Health Care
OpenAlex ID:
A5083513625
Monoclonal antibody successes in the clinic
2005
·
Janice M Reichert
, Clark J Rosensweig
, et al.
·
Nature Biotechnology
·
741
Competitiveness in follow-on drug R&D: a race or imitation?
2010
·
Joseph A. DiMasi
, Laura B. Faden
·
Nature Reviews Drug Discovery
·
94
Racial Disparities Among Clinical Research Investigators
2008
·
Kenneth Getz
, Laura Faden
·
American Journal of Therapeutics
·
88
Patient access to pharmaceuticals: an international comparison
2007
·
Joshua Cohen
, Laura Faden
, et al.
·
The European Journal of Health Economics
·
61
Comparing Patient Access to Pharmaceuticals in the UK and US
2006
·
Joshua Cohen
, Catherine Cairns
, et al.
·
Applied Health Economics and Health Policy
·
46
Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence
2010
·
Laura Faden
, Catherine Vialle-Valentin
, et al.
·
Health Policy
·
45
Factors Associated with Multiple FDA Review Cycles and Approval Phase Times
2009
·
Joseph A. DiMasi
, Laura Faden
·
Drug Information Journal
·
22
Off-label use reimbursement.
2009
·
Joshua Cohen
, Andrew Wilson
, et al.
·
PubMed
·
16
Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?
2008
·
Laura B Faden
, Christopher-Paul Milne
·
PubMed
·
12
Assessing the Performance of the EMEA’s Centralized Procedure: A Comparative Analysis with the US FDA
2008
·
Laura B. Faden
, Kenneth I. Kaitin
·
Drug Information Journal
·
7
Are Medicare plans complying with CMS regulation?
2008
·
Joshua Cohen
, Brian Young
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
·
2
Comment: Assessment of Changes in Utilization of Health-Care Services after Implementation of a Prior Authorization Policy for Atypical Antipsychotic Agents
2011
·
Laura Faden
, Stephen B Soumerai
·
Annals of Pharmacotherapy
Mapping Biopharmaceutical Innovation and Diffusion: How the Second Translational Block (T2) Shapes Drug Diffusion
2008
·
Joshua Cohen
, Laura Faden
, et al.
·
The Open Pharmacology Journal
PDF
Show more works
View as search
Works count:
14
Citation count:
1,134
H-index:
9
I10-index:
9
Year
Topic
Type
